Аннотация:The use of immunotherapy in the treatment of metastatic lung cancer has revolutionized patient care, significantly improving survival rates. Studies have demonstrated a strong correlation between PD-L1 levels and overall, recurrence-free survival in patients receiving immunotherapy for metastatic NSCLC. Building on the success of these studies, immunotherapy has moved to early stages, improving event free survival and, probably, overall survival in patients. We sought to analyze our own clinical experience of neoadjuvant Ch-IO and evaluate the role of PD-L1 expression as a predictive marker of achieving pCR and MPR in a real world clinical practice of a large community based comprehensive cancer center.